Peer Review Affirms MiSight® 1 day Sustains Slowing of Eye Growth Over 6 Years for Myopia Control
A new peer review paper affirms that CooperVision® MiSight® 1 day contact lenses provide myopia control for nearly all age-appropriate children. In the longest-running soft contact lens study among children, 90% of myopic eyes responded to MiSight® 1 day wear with a proportional treatment effect, meaning that younger and faster progressing children receive the maximum benefit. Evidence also indicated a sustained slowing of eye growth over time.
These findings are published in the March 2022 edition of Optometry and Vision Science, the peer review journal of the American Academy of Optometry. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial (Chamberlain P, et al.) is now available via Open Access.
The peer-reviewed six-year paper complements additional CooperVision research demonstrating that the lens slows the rate of myopia progression by an average of approximately 50% at all observed ages.
The data also support that it’s never too late to start treatment, as the lens halves myopia progression in older children as well. “Myopia is a disease that progresses over many years, so demonstrating sustained efficacy is critical,” said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision Director of Research Programs.
The MiSight® 1 day study is the longest running soft contact lens clinical trial for myopia management in age-appropriate children.
Click HERE for the full press release.